TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

• Research Methodology
• Global & Regional Market Analysis
• Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion
• Market and Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 1 Drugs
• Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026
• Future Market Assessment By Indication Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Key Market Dynamics
• Competitor Landscape

Download Report:

https://www.kuickresearch.com/report-global-trop-2-antibody-adc-drug-conjugate-market-sales-trodelvy-sacituzumab-govitecan

Triple negative breast cancer accounts for approximately 15%-20% of the cases and is mainly characterized by lack of expression of estrogen receptor (ER), progestrone receptor (PR) and human epidermal growth factor receptor-2 (Her-2). Despite the discovery of several targeted therapies in wide range of cancers, only limited targeted drugs have been approved for the management of TNBC patients owing to its high aggressive nature. Several researchers have revealed potential molecular targets and different drug types which have make their way into the market. Recently, scientists have identified trophoblast cell-surface antigen 2 as a potential therapeutic target for triple negative breast cancer.

Extensive research activities in this field have led to the development of several TROP2 directed drugs. Trodelvy (Sacituzumab govitecan/IMMU-132) is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate developed by Immunomedics which has been approved for commercial use. It targets the Trop-2 antigen through humanised monoclonal antibody, expressed on various tumour cells and delivers SN-38, a topoisomerase I inhibitor, to the tumours directly, causing cell death.The clinical trials with the drug demonstrated high efficacy and considerable increase in overall survival and progression free survival rates of triple negative breast cancer patients.

The approval of drug Trodelvy in 2020 is thought to revolutionize the paradigm treatment of metastatic triple negative breast cancer patients. It is expected that in short span of time, the drug will constitute a major share in the breast cancer therapeutics owing to its specific and selective nature towards cancer cell. It is analyzed that the market will witness high compound annual growth rates to reach a value of US$ 4 Billion by 2026. Apart from this, the favorable reimbursement policies by government including Trodelvy Access Service will help in lowering the overall cost of the therapy, further fueling the growth of market for next few years.

Apart from its expression in TNBC, the receptor is also over-expressed in several other cancers including non-small cell lung cancer, colon cancer, prostate, gastric, and urothelial cancers. Therefore, several ongoing clinical trials are evaluating the role of drug in other cancers including hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer, endometrial carcinoma, urothelial cancer, glioblastoma and hepatocellular carcinoma. Additional clinical trials are also evaluating the combination of drug with talazoparib, nivolumab, carboplatin, and other cancer therapeutics to enhance the efficacy of the drug. Te extended approval of the drug in other therapeutic conditions will also propel the growth of market.

The increasing sales of Trodelvy has also surged further research and development in this sector. To date, a cocktail of Trop 2 targeted therapies are currently present in clinical trials which are expected to enter the market duing forecast period. The pipeline of Trop 2 targeting drugs is highly crowded and consists of several candidates including DS-1062a, RN927C, BAT8003, SKB264, and JS108. Apart from this, pharmaceutical giants have entered into collobartion or partnerships to drive the researcg and development in this sector. For instance, Sorrento partnered with Escugen Biotechnology to evaluate recombinant humanized anti-Trop2 Mab-SN38 Conjugate.

The coming years will witness high growth rate in global Trop2 targeted therapies owing to increase in geriatric population and subsequent increase in prevalence of cancer. The growing demand of targeted therapies and the encouraging response of approved drugs will also drive the market in coming years. Moreover, the increasing number of product launches and the rising adoption rates of targeted treatments due to its higher achievement in terms of efficient treatment leading to improved patient outcomes are expected to contribute to the growth of market at higher compound annual growth rates during the forecast period.

Contact:

Neeraj Chawla
Research head
Kuick Research
neeraj@kuickresearch.com
+91-9810410366

India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.